EJMC 2020
DOI: 10.31487/j.ejmc.2020.01.01
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical In-House Validation of Commercially Available Fluorescence In-Situ Hybridization Probes Used in Diagnosis of Haematological Malignancies

Abstract: World Health Organization states the importance of conventional cytogenetics and FISH in hematological malignancy for accurate diagnosis, treatment and monitoring response to therapy. Most FISH probes, however, are Analyte- Specific reagents (not FDA approved) and thus an elaborate validation procedure prior to diagnostic use becomes essential. This study focuses on validating FISH probes by assessing the analyte- sensitivity, specificity, accuracy, precision and determining normal reference ranges (cut-offs).… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 4 publications
0
1
0
Order By: Relevance
“…Before putting the probe in use, other factors like probe verification, specificity, and sensitivity should be confirmed and documented for every new lot received. 63…”
Section: Quality Control For Fluorescence In Situ Hybridization Probesmentioning
confidence: 99%
“…Before putting the probe in use, other factors like probe verification, specificity, and sensitivity should be confirmed and documented for every new lot received. 63…”
Section: Quality Control For Fluorescence In Situ Hybridization Probesmentioning
confidence: 99%